Fenwick & West represented Almirall, S.A. (ALM), a leading global pharmaceutical company focused on medical dermatology, in its agreement with 23andMe, a leading consumer genetics and research company.
23andMe has the world's largest set of genotypic information paired with billions of phenotypic data points contributed by engaged customers. 23andMe's dedicated Therapeutics group identifies novel targets using the 23andMe database, generates lead compounds to these targets and performs preclinical research to support future clinical development.
Based upon strong genetic evidence, 23andMe's team generated a bispecific antibody that blocks the IL-36 cytokine family. IL-36 is a part of the IL-1 cytokine family, which is associated with multiple inflammatory diseases, including various dermatological conditions.
Almirall’s agreement with 23andMe allows Almirall to in-license 23andMe's bispecific monoclonal antibody designed to block all three members of the IL-36 cytokine subfamily. Almirall will secure the rights to develop and commercialize the antibody for worldwide use. This agreement reinforces Almirall’s early-stage portfolio in dermatology, including orphan indications.
More information about the agreement can be obtained from Almirall's announcement.
The Fenwick transaction team was led by intellectual property counsel Claire O’Callaghan.